Harry Wilcox Chief Operating Officer and General Partner, Flagship Ventures
Harry Wilcox brings a rich set of experiences and expertise in financial management, operations, fund management and strategy to the Tangent Medical Board of Directors.
As COO and General Partner at Flagship Ventures, Harry oversees the firm's financial operations and LP relations/fundraising, and serves as board member or advisor to select portfolio companies.
Harry is currently a board member of Black Duck, Celexion, Seahorse Bioscience, Seventh Sense Biosystems and T2 Biosystems.
career spans 30 years and has involved many different roles and functions including Controller, CFO
, Sr. VP BD
, and CEO.
He has also served on several Boards of Directors.
Most recently he has served as CFO and then Sr. VP Corporate Development for EXACT Sciences (NASDAQ:EXAS), one of Flagship's portfolio companies, and on the Board of another portfolio company, Epitome Biosystems.
In addition to his corporate experience, Harry was previously CFO of two venture capital firms, Highland Capital Partners where he was the founding CFO and General Partner, and prior to that, Charles River Ventures.
has also led an active consulting practice, which included roles as interim CEO of biotech companies Thrasos Therapeutics and Biostratum.